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A B S T R A C T
A double mutation (KM670/671NL) in amyloid precursor protein gene (APP) is causative for familial Alzheimer's disease and has been shown to increase the total Aβ
burden. Here we report the generation and characterization of an iPSC line from a fAD patient carrying APP KM670/671NL. The generated iPSCs retained the
mutation, expressed pluripotency markers, showed a normal karyotype and differentiated into all three germ layers. This iPSC line can be used, for example, in
disease modeling and mechanistic studies.
Resource table.
Unique stem cell line
identifier
UEFi002-A
Alternative name(s) of stem
cell line
LL008 1.4





Type of cell line iPSC
Origin Human
Additional origin info Age: 58
Sex: Female
Ethnicity: Scandinavian
Cell Source Skin fibroblasts
Clonality Clonal
Method of reprogramming Sendai virus carrying OCT3/4, SOX2, KLF4 and c-MYC
(CytoTune 1.0)
Genetic Modification No
Type of Modification N/A
Associated disease Familial Alzheimer's disease
Gene/locus APP (MIM # 104760) located on the long arm of chromosome 21 at position 21q21.3; 27,269,939 G > T,
27269938 A > C (rs63751263, rs63750445)
Method of modification N/A
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Date archived/stock date March 2016
Cell line repository/bank N/A
Ethical approval Ethical license number 2017/834–31/1 (The ethical review board of Karolinska Institutet/Karolinska University
Hospital)
Resource utility
Mutations in amyloid precursor protein (APP) gene are a well-re-
cognized cause of early-onset Alzheimer's disease (AD). APP KM670/
671NL mutation is the only known mutation adjacent to the beta-se-
cretase cleavage site of APP. This iPSC line can be used in in vitro disease
modeling to decipher the early pathological mechanisms.
Resource details
APP KM670/671NL double mutation was first found in the early
1990's from two Swedish families (Mullan et al. 1992). This mutation is
located directly adjacent to the beta-secretase cleavage site of APP
protein and is known to significantly increase the total beta-amyloid
(Aβ) burden, leading to familial AD in humans. APP KM670/671NL
mutation is widely used in transgenic AD animal models to induce Aβ
plaque formation. However, the human studies are mostly limited to
post-mortem brains. Here, we report the generation and characteriza-
tion of an induced pluripotent stem cell line from a patient carrying the
APP KM670/671NL (Swedish) mutation.
Skin fibroblasts were obtained by skin biopsy after informed consent
from a 58-year old female carrying the APP KM670/671NL (Swedish)
mutation and diagnosed with early-onset familial Alzheimer's disease.
Fibroblasts were reprogrammed using CytoTune™ 1.0 iPS Sendai
Reprogramming Kit. Emerging colonies were mechanically lifted from
feeders and grown as individual clones. Five clones were selected for
further expansion and characterization based on their morphology and
growth properties. Here, we present the detailed characterization of
clone LL008 1.4 (Table 1) using methods described in detail previously
(Oksanen et al. 2017; Holmqvist et al. 2016).
The generated iPSC line LL008 1.4 presented typical colony shape
and morphology when grown on human foreskin fibroblast feeders
(Fig. 1A), and colonies stained positive for nuclear pluripotency markers
OCT4 and NANOG, and surface proteins TRA 1–81 and SSEA4 (Fig. 1B).
iPSCs expressed high levels of typical pluripotency-regulating genes
SOX2, NANOG and LIN28 as compared to parental fibroblasts by real-
time quantitative PCR (Fig. 1C). Sendai virus was no longer expressed
when iPSCs were analyzed at passage 15 and compared to SeV-trans-
duced fibroblasts (Fig. 1C). Cells showed normal female karyotype in
the chromosomal analysis at passage 23 (Fig. 1E). The identity of the
iPSCs was confirmed with STR analysis showing an identical genetic
background with the parental fibroblasts (data available with the au-
thors). The presence of the heterozygous double APP KM670/671NL
mutation was confirmed from genomic DNA with Sanger sequencing of
the APP loci (Fig. 1F). Finally, LL008 1.4 line spontaneously formed
embryoid bodies (EBs) when cultured in suspension in ultra-low at-
tachment plate (Fig. 1G). The formed EBs were plated down for 14 days,
and the outgrowing cells represented cell types from all three germ
layers, including alpha-fetoprotein (AFP) positive endodermal cells,
smooth muscle actin (SMA) positive mesodermal cells and beta-III-tu-
bulin (TUJ1) positive ectodermal cells (Fig. 1G). A luminescence-based
mycoplasma detection test was clearly negative as compared to negative
(media only) and positive control (from manufacturer) (Fig. 1D).
Materials and methods
Fibroblast culture
Skin biopsy was obtained from a familial AD patient carrying APP
Swedish mutation after written informed consent. Fibroblasts were
maintained in a standard CO2 incubator with 5% CO2 at 37 °C. Culture
medium consisted of IMDM (Invitrogen) supplemented with 20% FBS
(Biowest), 1% NEAA (Sigma-Aldrich) and 1% penicillin/streptomycin
(Invitrogen), and cells were passaged using TrypLE Express (Invitrogen).
iPSC generation
Fibroblasts were reprogrammed with Cytotune 1.0 iPS Sendai
Reprogramming Kit (Invitrogen). Briefly, MOI 3 of each of the vectors
(OCT4, SOX2, KLF4, and c-MYC) was used, and culture medium was
supplemented with 0.5 mM sodium butyrate (Sigma-Aldrich) for at least
10 days after transduction (until colonies started to emerge). One week
after transduction, cells were transferred to grow on top of mitotically
inactivated (10 μg/ml mitomycin-C for 2.5 h in 37 °C) human foreskin
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: Normal morphology Fig. 1 panel A
Phenotype Qualitative analysis:
Immunocytochemistry
Positive staining of pluripotency markers OCT4, NANOG, TRA 1–81 and SSEA4 Fig. 1 panel B
Quantitative analysis:
RT-qPCR
High expression levels of pluripotency markers SOX2, NANOG and LIN28 as
compared to parental fibroblasts and absence of SEV expression
Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution Normal karyotype 46, XX,
resolution 300–400 bands in average
Fig. 1 panel E
Identity STR analysis 7 sites tested, all matched with parental fibroblasts Available with the
authors
Mutation analysis Sequencing Heterozygous double point mutation KM670/671NL in APP gene Fig. 1 panel F
Microbiology and virology Mycoplasma testing by luminescence Negative Fig. 1 panel D
Differentiation potential Embryoid body (EB) formation Spontaneous EB formation and positive staining of three germ layer markers α-
fetoprotein (AFP), smooth muscle actin (SMA) and beta-III-tubulin (TUJ1).
Fig. 1 panel G
Donor screening HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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Fig. 1. Characterization of iPSC line LL008 1.4.
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fibroblast (from ATCC). The next day, medium was changed to stem cell
medium consisting of knockout DMEM (Invitrogen) supplemented with
20% KOSR (Invitrogen), 1% NEAA (Sigma-Aldrich), 2 mM Glutamax
(Invitrogen), 1% penicillin/streptomycin (Invitrogen), 0.1 mM 2-mer-
captoethanol (Sigma-Aldrich) and 10 ng/ml bFGF (Peprotech). The
emerged colonies were individually subcloned and passaged mechani-
cally with a scalpel once a week (on average 40 colony pieces per
35mm2 plate). For differentiation and karyotyping, iPSCs were cultured
in feeder-free conditions with Matrigel (BD Biosciences) and Essential 8
culture medium (Life Technologies). Cells were passaged with 0.5mM
EDTA (Life Technologies) every 5–7 days using split ratio 1:15–1:20,
and 5 μM ROCK-inhibitor Y-27632 (Sellechchem) was added to the
medium for the first 24 h.
Embryoid body formation
iPSC colonies were cultured in suspension for 2 weeks using ultra-
low attachment plates (Corning). Rounded EBs were plated down on
matrigel-coated coverslips for 2 weeks before analysis. Culture medium
consisted of stem cell medium without bFGF and Essential 8 culture
medium at 1:1 ratio and it was changed three times a week. The same
media was used throughout the experiment.
Karyotype analysis
iPSCs were treated with 200 ng/ml KaryoMAX® Colcemid™ Solution
(Invitrogen) for 16 h in the incubator. Karyotyping was performed at the
Eastern Finland Laboratory Centre Joint Authority Enterprise (ISLAB,
Kuopio, Finland) using Giemsa staining protocol. Total of 20 meta-
phases were analyzed.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 20min at room
temperature (RT) and permeabilized with 0.2% TritonX (except surface
markers) for 1 h at RT. Unspecific binding sites were blocked with either
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID








EMD Millipore; cat # MAB4401
RRID: AB_2167852
R&D Systems; cat # AF1997
RRID: AB_355097
EMD Millipore; cat # MAB4304
RRID: AB_177629
EMD Millipore; cat # MAB4381
RRID: AB_177638






Sigma-Aldrich; cat # A8452
RRID: AB_258392
Sigma-Aldrich; cat # A5228
RRID: AB_262054
Covance; cat # MMS-435P
RRID: AB_2313773
Secondary antibodies Goat anti-mouse Alexa Fluor 488
Goat anti-mouse Alexa Fluor 568




Molecular Probes, cat # A11001
RRID: AB_2534069
Molecular Probes; cat # A11004
RRID: AB_141371
Molecular Probes; cat # A11057
RRID: AB_142581
Primers
Target Forward/Reverse primer 5′-3′ (expected product size)
Targeted mutation analysis and sequencing (forward primer only) APP TGGCAAGACAAACAGTAGTGG/
CTTGCCAACCTCTCAACCAG (453 bp)














Pluripotency markers (qPCR) SOX2
NANOG
LIN28
Thermo Fisher Scientific; cat # Hs01053049_s1
Thermo Fisher Scientific; cat # Hs02387400_g1
Thermo Fisher Scientific; cat # Hs00702808_s1
House-keeping gene (qPCR) Human beta-actin (ACTB) Thermo Fisher Scientific; cat # 4326315E
Reprogramming virus (qPCR) Sendai virus (SEV) Thermo Fisher Scientific; cat # Mr04269880_mr
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5% normal goat serum or 0.1% bovine serum albumin for 1 h at RT.
Primary antibodies were incubated overnight in the fridge, followed by
incubation with secondary antibodies for 1 h at RT. Nuclei were coun-
terstained with Hoechst 33,258 (Sigma) for 15min at RT. Coverslips
were mounted with Fluoromount G mounting media (Southern Biotech)
before acquiring images with either Olympus IX71 or Olympus AX70
fluorescent microscopes.
RNA extraction and RT-qPCR
RNA was extracted and reverse-transcribed with TaqMan® Gene
Expression Cells-to-CT™ Kit (Applied Biosystems). RT-qPCR was per-
formed with TaqMan assay mixes and TaqMan Gene Expression Master
Mix using StepOne Plus™ Real-Time PCR machine. Expression levels
were normalized to housekeeping gene beta-actin using Q-gene program
(Equation 2).
Genetic analysis
Genomic DNA was extracted with GeneJET Genomic DNA
Purification Kit (Thermo Fisher Scientific). The presence of the mutation
was verified with Sanger sequencing from the PCR product (primers in
Table 2, Tm 57 °C). The genetic identity was confirmed using seven
microsatellite loci and analyzed by PCR and gel electrophoresis (primers
in Table 2, Tm 55 °C for all). All PCRs were run with Biorad T100
thermal cycler using standard cycle parameters: 3 min at 94 °C, followed
by 35 cycles of 94 °C for 30 s, Tm for 30 s and 72 °C for 45 s, and finally
72 °C for 5min.
Mycoplasma testing
Cultures were tested for mycoplasma contamination using the lu-
minescence-based MycoAlert™ Mycoplasma Detection Kit (Lonza).
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